Abstract |
Newer topical therapies approved by the US Food and Drug Administration (FDA) for the treatment of acne vulgaris are dapsone gel 5% and clindamycin phosphate 1.2% and tretinoin 0.025% combination gel. Both are formulated in aqueous-based gel vehicles. These newer topical acne products have been shown to be effective and safe in pivotal 12-week phase 3 trials and long-term studies completed over 12 months. This article reviews applicable pharmacokinetic, efficacy, and safety data reported with both products.
|
Authors | James Q Del Rosso |
Journal | Cutis
(Cutis)
Vol. 80
Issue 5
Pg. 400-10
(Nov 2007)
ISSN: 0011-4162 [Print] United States |
PMID | 18189027
(Publication Type: Journal Article, Review)
|
Chemical References |
- Anti-Infective Agents
- Drug Combinations
- Keratolytic Agents
- Clindamycin
- Tretinoin
- Dapsone
|
Topics |
- Acne Vulgaris
(drug therapy)
- Administration, Topical
- Anti-Infective Agents
(pharmacology)
- Clindamycin
(pharmacology)
- Dapsone
(pharmacology)
- Drug Combinations
- Humans
- Keratolytic Agents
(pharmacology)
- Treatment Outcome
- Tretinoin
(pharmacology)
|